{"url_path":"/sec/tbph/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1583107/0001104659-26-078453-index.html","accession_number":"0001104659-26-078453","cik":"0001583107","ticker":"TBPH","issuer_name":"Theravance Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583107/0001104659-26-078453-index.html","primary_entity_key":"0001583107","primary_entity_name":"Theravance Biopharma, Inc."},"word_count":136,"has_tables":true,"body_markdown":"**Item 7.01.**\n**Regulation FD\nDisclosure.**\n\n \n\nOn June 29, 2026, the\nCompany provided supplemental information regarding the Merger in communications to Company employees. Copies\nof those communications are furnished as Exhibits 99.2 and 99.3 and are incorporated herein by reference.\n\n \n\nThe information contained\nin Item 7.01 of this report, including the communications attached as Exhibits 99.2 and 99.3, is furnished pursuant to Item 7.01 of Form 8-K and\nshall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act, as amended (the “Exchange\nAct”) or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under\nthe Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set\nforth by specific reference in such a filing."}